GlassScriptPhysician profile
Russell E Dickenson
NPI 1497745814
$7,687.20
in general payments reported to CMS, 2019-2025
31 companies · $1,521 in 2025
The $1,521 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,009 · 2022: $1,604 · 2023: $1,404 · 2024: $1,150 · 2025: $1,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,074.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,426.97 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $965.03 | 2021-2025 | Lifevest |
| Amgen INC. | $617.72 | 2021-2025 | Repatha, Repatha |
| Pfizer INC. | $595.80 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $552.42 | 2021-2025 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $532.07 | 2021-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $400.89 | 2021-2023 | Xarelto |
| Novo Nordisk INC | $334.65 | 2022-2025 | Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $276.09 | 2021-2025 | Nexletol |
| Philips North America LLC | $231.82 | 2022-2024 | (Ck4) Mcot |
| Merck Sharp & Dohme LLC | $227.21 | 2021-2025 | Verquvo, Capvaxive, Steglatro |
| E.R. Squibb & Sons, L.L.C. | $220.22 | 2021-2025 | Camzyos, Eliquis |
| Scpharmaceuticals INC. | $159.29 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.05 | 2021-2023 | Jardiance |
| Amarin Pharma, INC. | $128.26 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $128.25 | 2022-2025 | |
| Daiichi Sankyo INC. | $105.55 | 2022-2024 | Injectafer |
| Sanofi-Aventis U.S. LLC | $91.00 | 2022-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $87.56 | 2024 | Arcalyst |
| Cvrx, INC. | $79.48 | 2023-2024 | Barostim Neo System |
| Baxter Healthcare | $72.05 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Boston Scientific Corporation | $59.46 | 2025 | Bodyguardian, General - Therapies |
| Abbott Laboratories | $47.50 | 2021-2023 | Aveir |
| Medtronic, INC. | $42.00 | 2021-2023 | Linq II |
| Neurelis, INC. | $36.60 | 2024 | Valtoco |
| Ucb, INC. | $29.39 | 2024 | Briviact |
| Mallinckrodt Hospital Products INC. | $27.68 | 2025 | Acthar |
| Inspire Medical Systems, INC. | $24.13 | 2025 | Inspire |
| Heartflow, INC. | $20.98 | 2025 | |
| Argenx US, INC. | $13.58 | 2025 | Vyvgart |
| Vivaquant INC, Dba Rhythm Express | $4.50 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Dickenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.